Watchlist Price Alert

TScan Therapeutics Inc. (TCRX)

NASDAQ: TCRX · Real-Time Price · USD

1.70

-0.08 (-4.49%)

At close: Jun 05, 2025, 1:42 PM

-4.49% (1D)

Bid	1.69
Market Cap	95.92M
Revenue (ttm)	4.42M
Net Income (ttm)	-131.48M
EPS (ttm)	-1.08
PE Ratio (ttm)	-1.57
Forward PE	-1.48
Analyst	Buy

Ask	1.7
Volume	111,524
Avg. Volume (20D)	588,384
Open	1.72
Previous Close	1.78
Day's Range	1.68 - 1.79
52-Week Range	1.02 - 9.29
Beta	0.97

About TCRX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TCRX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TCRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

News

4 weeks ago · zacks.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.32 per share a year ago.

2 months ago · seekingalpha.com

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

Additional data from phase 1 ALLOHA study, using TSC-101 for the treatment of patients with hematological malignancies of those undergoing allogeneic haploidentical HSCT, expected by end of 2025. Barr...

3 months ago · zacks.com

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.21 per share a year ago.